Potential Alzheimer’s disease drug targets identified through microglial biology research

IF 6 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert Opinion on Drug Discovery Pub Date : 2024-04-08 DOI:10.1080/17460441.2024.2335210

Izabela Lepiarz-Raba, Taufik Hidayat, Anthony J. Hannan, Ali Jawaid

引用次数: 0

Abstract

Microglia, the primary immune cells in the brain, play multifaceted roles in Alzheimer’s disease (AD). Microglia can potentially mitigate the pathological progression of AD by clearing amyloid beta...

查看原文本刊更多论文

通过小胶质细胞生物学研究确定阿尔茨海默病潜在药物靶点

小胶质细胞是大脑中的主要免疫细胞，在阿尔茨海默病（AD）中发挥着多方面的作用。小胶质细胞可以通过清除淀粉样蛋白β来缓解阿尔茨海默病的病理进展...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Drug Discovery 医学-药学

CiteScore

10.20

自引率

1.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development. The Editors welcome: Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.